Silicon Valley BioTalks is a unique venue for company representatives to interact and exchange insight about current industry trends.
Palo Alto, CA (PRWEB) October 11, 2011
Clinovo sponsors the upcoming Silicon Valley BioTalks event, taking place in Palo Alto, CA, on November 2nd 2011, 6:30 PM. A panel of clinical trial experts will discuss how to successfully run adaptive clinical trials.
Panelists from leading pharmaceutical and biotechnology companies will address key benefits and limitations of adaptive clinical trials. The panel includes representatives from Theravance, Xenoport, MAP Pharmaceuticals, Arincal, ARA, and Clinovo. Leveraging years of experience and expertise, they will explain how adaptive designs help streamline the clinical trial process.
Adaptive clinical trials offer enormous potential in today's drug development process. They facilitate decision making by enabling multiple arms to be studied while maintaining practical sample sizes. They also reduce the time between development phases, using seamless designs and aid in the early identification of failing compounds. The FDA shares the interest of drug developers in these advantages, but is also concerned with several aspects of this approach, such as the possibility to introduce bias and incorrect conclusions.
The participants on the panel will share with the audience their best practices on how to successfully implement adaptive clinical trials. How do you plan ahead for an adaptive clinical trial? What are the main advantages of this method and the main risks? What are the strategies for use of adaptive design? These are some of the questions the panelists will address and discuss with the attendees.
The panel is composed of high-level executives from leading biotechnological and pharmaceutical companies:
- Peter Shabe, President of Advance Research Associates;
- Hilary Carlson, Independent Clinical Research Consultant at ARINCAL;
- Oranee Daniels, M.D., Vice President in charge of Clinical Pharmacology and Experimental Medicine at Theravance;
- Don Kellerman, Senior Vice President in charge of Clinical Development and Medical Affairs at MAP Pharmaceuticals;
- Daniel Bonzo, Senior Director and Head of Biometrics and Data Management at Xenoport;
- Moderated by Pascal Royet, newly appointed VP of Business Operation at Clinovo.
Silicon Valley BioTalks is a premier discussion forum to learn about new technologies and best practices for clinical trials. “Silicon Valley BioTalks is a unique venue for company representatives to interact and exchange insight about current industry trends”, says Peter Shabe, President of Advance Research Associates.
The first meeting of Silicon Valley BioTalks was met with great enthusiasm, with over a hundred representatives of biotechnology, medical device and pharmaceutical companies from the San Francisco Bay Area. “We are very excited to bring together for this new BioTalks event many of the industry’s top executives to discuss the promises and key concerns of adaptive clinical trials”, says Ale Gicqueau, President and CEO of Clinovo, and leading sponsor of the event.
This upcoming Silicon Valley BioTalks event “Planning ahead for an adaptive clinical trial” is free of charge with pre-registration. Complimentary food and drinks will be provided.
Topic: Planning ahead for an adaptive clinical trial
When: Wednesday, November 2nd – 6:30 PM – 8:00 PM PST
Where: SNR Denton US LLP
Tashkent Conference Room
1530 Page Mill Road - Suite 200
Palo Alto, CA 94304-1125
Space is limited. Register now for free at http://www.clinovo.com/silicon_valley_biotalks/adaptive_clinical_trial
About Silicon Valley BioTalks
Silicon Valley BioTalks is a series of events that include discussion and networking. It is sponsored by Clinovo and SNR Denton, and is the meeting place in the Silicon Valley where industry professionals share knowledge about technology and best practices for clinical trials.